Oxford BioMedica may have a cure for leukaemia. Its share price has soared since the last week of June. Its treatment uses a modified version of the HIV virus to insert a cancer-killing gene into patients' cells. This is a stunning example of how gene therapy will revolutionise medicine in the future. And there are many other players working in the incredible field of gene therapy. More widespread genome sequencing opens up the possibility of personalised treatments. The news coming out of the laboratories is encouraging – not least for investors.
John Dawson, CEO of Oxford BioMedica (LON:OXB) has been preparing the firm's Oxford laboratories for some important visitors. Any day now, a team of white-coated technicians from America's Food and Drug Administration (FDA) will call by to inspect. If they like what they see, then OXB's new drug – CTLO19 – could be licensed for use in the USA by as early in October. A European Medicines Agency (EMA) filing is likely to follow soon after.
This new drug uses a stripped-down version of the HIV virus to reprogram a cancer-sufferer's immune system to kill cancer cells. In a treatment that OXB devised in partnership with Swiss pharma giant Novartis AG (VTX:NOVN) and the University of Pennsylvania, the drug can be administered by one simple injection.
by John Kingham| Equities| 10 mins. to read AstraZeneca (LON:AZN) and GlaxoSmithKline (LON:GSK) are the two pharmaceutical giants of the FTSE 100. They are also both high yield dividend stocks with yields of more than 4%. Another notable fact is that both companies have been long-term holdings of a certain Mr Neil Woodford.
by Robert Stephens| Equities| 2 mins. to read Recovery stocks can be among the most profitable investments. One reason for this is that the market usually expects disappointing financial performance from them, which generally means low valuations.
Material contained within Master Investor Magazine and its website is for general information purposes only and is not intended to be relied upon by individual readers in making (or refraining from making) any specific investment decisions. Master Investor Ltd. does not accept any liability for any losses suffered by any user as a result or any such decision.
Ingen kommentarer:
Send en kommentar